Peakdale Molecular Management Team
Please click on the links below the pictures to find out more about Peakdale Molecular’s Management Team:
From 1981 to 1996, Paul held a variety of senior positions in research for the Wellcome Foundation at Beckenham in Kent, culminating in Senior Research Scientist for the Drug Discovery Unit.
Paul was most recently Technical Director at BioFocus (now BioFocus DPI, a Galapagos company) where between 1997 and 2003, he was a founding scientist and Director of Chemistry.
Paul holds a degree in chemistry from New College, Oxford and achieved his D. Phil. at the University of Sussex in 1981. He has previously been Secretary to the UK Peptide and Protein Group and was one of the instigators of the BioMolecular Structure Unit at the University of Sussex.
David joined Peakdale in 2003, and since then has successfully managed numerous teams and projects for global pharmaceutical and biotechnology companies across a wide range of therapeutic areas.
He gained his first degree from the University of Bradford and was awarded his PhD in 2003 from the University of Sheffield, working on nucleophillic catalysis under the tutelage of Alan Spivey.
David is currently a member of SCI’s Fine Chemicals Group and holds an MBA from the University of Bradford, School of Management. He is a Fellow of the Royal Society of Chemistry (FRSC) and has responsibility for all chemistry activities at our Chapel site.
Gordon has a BSc in Applied Microbiology and joined Peakdale in 2015 bringing over 25 years of commercial experience.
Gordon held a number of senior positions in companies offering scientific services to the pharmaceutical and biotech industries and was responsible for business development and strategic alliances at Proteros Biostructures. Whilst there Gordon played a key role in Proteros’ growth. Before this Gordon was responsible for European Business development at Codexis Inc.
Gordon is responsible for business development across the company
Paul joined Peakdale Molecular in September 2016 as Head of Chemistry at its Sandwich site.
Paul holds a PhD in Synthetic Organic Chemistry (Leeds University) and has 25 years’ post doctoral experience in the UK pharmaceutical and CRO industries. Prior to joining Peakdale Molecular he created a medicinal chemistry operation at Charnwood Molecular which enabled the company to offer a medicinal chemistry service to its clients and thus double in size as a consequence. Prior to this Paul worked as a synthetic medicinal chemist at Knoll Pharmaceuticals (11 years) and then as a Project Leader at Pfizer (10 years) in Sandwich.
He has worked on diverse classes of medicinal chemistry targets in a variety of therapeutic areas. These include opioid agonists and ion channel modulators (pain), progesterone antagonists, beta-3 agonists, NK2 inhibitors (urology), soluble guanylatecyclase inhibitors and NEPi inhibitors (cardiovascular), D2 antagonists/5-HT1a agonists (antipsychotics) and other targets in the obesity, oncology and immunology therapeutic areas.
Paul has a proven track record of success in medicinal chemistry helping to deliver 12 NCE’s into development and 3 small molecules into Phase 2 clinical trials. This is supported by an impressive publication record in both medicinal and synthetic chemistry (approximately 30 scientific publications which are patents, papers and reviews).
Chris joined Peakdale in 2016 as Head of Biology. Prior to this, he was Head of Safety Pharmacology and Systems Pharmacology groups at Almirall Spain, where he was responsible for the pharmacology support and preclinical development of the respiratory and inflammatory drug discovery projects, several of which have transitioned to the clinic.
At GSK Chris spent a number of years working in the cardiovascular and urogenital drug discovery group in Philadelphia and has experience in leading programs from target validation through to candidate selection. His disease area expertise includes cardiovascular, renal, respiratory, inflammation , CNS and urogenital diseases. He is also an experienced Safety Pharmacologist.
Chris obtained his degree in pharmacology and PhD in Cardiovascular Physiology from the University of Leeds, followed by a post-doc with Pfizer in Groton.